Adalta Ltd. · ASX:1AD
Adalta — Shareholder Meeting (November 2023)
31 slides from Adalta's shareholder meeting presentation, Nov 22, 2023
Slide 1: Chairman's address – 2023 AdAlta Annual General Meeting
ASX Announcement | 22 November 2023 AdAlta Limited (ASX:1AD) Chairman’s address – 2023 AdAlta Annual General Meeting Ladies and gentlemen, Welcome to AdAlta’s 2023 Annual General Meeting My name is Paul MacLeman and it is my privilege to Chair the Board of AdAlta Ltd. Our purpose is to go where trad
Slide 2: Chairman's address (continued)
v. Next quarter we anticipate being able to report full immune response data, completing the last question partners are posing that can be answered without a clinical trial. Tim Oldham will talk more about this data in his address. It places us in a much more compelling partnering position than at t
Slide 3: Chairman's address: i-body inventory and financing
Build an “inventory” of well characterized i-bodies that can help initiate new co-development partnerships to add to our collaborations with Carina Biotech, GE Healthcare and GPCR Therapeutics During the year, collaborators published new functional data on an i-body against a target implicated in os
Slide 4: For further information, please contact
For further information, please contact: AdAlta Limited (ASX:1AD) Media & Investor Enquiries Tim Oldham The Capital Network CEO & Managing Director Julia Maguire P: +61 3 9479 5159 P: +61 2 8999 3699 E: t.oldham@adalta.com.au E: julia@thecapitalnetwork.com.au About AdAlta Limited AdAlta Limited is a
Slide 5: A modern targeting system for next generation drugs
A modern targeting system for next generation drugs AdAlta Limited (ASX:1AD) CEO Presentation to Annual General Meeting November 2023
Slide 6: Disclaimer
Disclaimer Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation for subscript
Slide 7: AdAlta (ASX:1AD): Progressing multiple transaction opportunities
AdAlta (ASX:1AD): Progressing multiple transaction opportunities Purpose: i-body® targeting for next generation therapeutics Going where antibodies can't to produce high-value, next generation protein and cell therapies for debilitating diseases Discovery business Product development business i-body
Slide 8: Substantial progress across three core strategies in 2023
Substantial progress across three core strategies in 2023 1. Realise the value of AD-214 v Linked receptor occupancy with efficacy for the first time v Commenced Phase I extension study ü Enabled dose simulation and estimation ü Advances Phase II preparation ü Substantially derisks Phase II clinical
Slide 9: Near-term opportunities for shareholders
Near-term opportunities for shareholders Attractive current valuation and fundamentals v Enterprise value ~A$5m* Share price performance (ASX:1AD) (12 months) 0.06 6.0 v Strong and supportive institutional register 0.05 5.0 v Differentiated technology and in-house R&D team 0.04 4.0 Share price (A$)
Slide 10: AD-214: new hope for fibrotic disease patients
AD-214: new hope for fibrotic disease patients
Slide 11: Bill van Nierop: IPF survivor on the challenge of living with IPF
Bill van Nierop: IPF survivor on the challenge of living with IPF “… sadly I am one of a few who can actually “I talked with a 60 something grandmother, who really enjoyed days looking after relate to the lived experience with and without PF grandkids, but as disease progressed she found sometimes s
Slide 12: Better outcomes are needed for Idiopathic Pulmonary Fibrosis and other fibrotic diseases
Better outcomes are needed for Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases 45% of developed world deaths IPF prevalence >490,000 worldwide have a chronic fibrosis component 72,000 78,000 Europe • Lung (US$4b) USA 14,000 Japan • Kidney (US$10b) 159,000 China 6,000 Slow, but do not
Slide 13: AD-214 is AdAlta's solution: A$45m investment has built a strong value proposition
AD-214 is AdAlta’s solution: A$45m investment to date has built a strong value proposition for partnering and for Phase II AD-214 features Benefit for partners and patients 1. First in class molecule targeting established mode of ü Only product entering Phase II with antibody-like action in fibrotic
Slide 14: Recent achievements #1: Potential IV efficacy verified; potential SC product
Recent achievements #1: Potential IV efficacy verified at clinical dosing regimens; potential SC product identified A. AD-214 has demonstrated efficacy in multiple animal models of fibrotic disease B. In humans, AD-214 was able to maintain more than 60% receptor occupancy (blocking) for up to three
Slide 15: Recent achievements #2: Phase I extension study supporting partnering and Phase II
Recent achievements #2: Phase I extension study supporting partnering and Phase II AD-214 multidose Phase I extension clinical study D E NCE M COM Establishes safety of AD-214 at likely maximum dose to be used in Phase II studies ü RECENT: 3x10 mg/kg doses well tolerated with no dose limiting toxici
Slide 16: Newest clinical data: Safety and receptor occupancy reinforce safety profile and dose selection
Newest clinical data: Safety and receptor occupancy reinforce IM ER INT LTS* safety profile and dose selection RE SU Receptor occupancy (RO) in line with model predictions for efficacy of 10 mg/kg infusion every two weeks Predicted RO Observed RO (mean) § >80% at one week after infusion ü >90% at on
Slide 17: The value: Pharma companies are actively licensing IPF assets for significant value
The value: Pharma companies are actively licensing IPF assets for significant value Upfront payment to Clinical Phase at Date Licensor/target Licensee/acquirer Transaction Contingent milestones licensor transaction Feb 23 Acquisition# US$294m N/A 2 Jan 23 China only license US$76m^ US$336m 2 Aug-22
Slide 18: Co-developed immuno-oncology programs: i-CAR-cell therapies
Co-developed immuno-oncology programs: i-CAR-cell therapies
Slide 19: The need: Multifunctional CAR-cell therapies
The need: Multifunctional CAR-cell therapies Therapy involves re-engineering patient’s own immune cells to “see” cancer – living drug, single dose, potentially curative 6 FDA-approved CAR-T therapies since 2017 transforming outcomes: Complete response rates: 83% r/r pALL, 51-65% r/r LBCL, 78% r/r MM
Slide 20: AdAlta's solution: i-bodies enable superior CAR constructs (i-CARs)
AdAlta’s solution: i-bodies enable superior CAR constructs (i-CARs) when combined with partner platforms TINY i-body® needs LESS room in inserted gene, enabling MORE engineered function Produces superior, multifunctional i-CAR products v Improved targeting § Novel tumor antigens, dual and bi-specifi
Slide 21: Three targets in development with Carina Biotech using repeatable partnering model
Three targets in development with Carina Biotech using repeatable partnering model i-body® platform cell therapy platform i-body® enabled CAR-T (i-CAR-T) cells have ü successfully demonstrated in vitro cancer cell line killing (lysis) i-CAR-Ts for solid tumor patients Target A: 3 A-i-CAR-T cells pro
Slide 22: The value: Cell & gene therapy up front deal values 3.5x higher than other biologics
The value: Cell & gene therapy up front deal values 3.5x higher than other biologic drugs with potential to partner early Asset in-licensing terms Pre-clinical proof of concept cell therapy transactions Cell & gene therapy Biologics Upfront/ Deal value/ 120 No. of Date Licensee Licensor target targe
Slide 23: Unlocking value in i-body pipeline
Unlocking value in i-body pipeline
Slide 24: AdAlta's portfolio: High value therapeutics in fibrosis and immuno-oncology
AdAlta’s portfolio: High value therapeutics addressing challenging diseases in fibrosis and immuno-oncology and a platform grow further Fibrosis: degenerative, progressive, fatal AdAlta’s AD-214 could meet a desperate need for new approaches for debilitating diseases of the lung (US$4.3b), kidney (U
Slide 25: Partnering momentum increasing to unlock asset value and build pipeline
Partnering momentum increasing to unlock asset value and build pipeline • Illustrative recent progress Out-licensing or co-investment for Phase II development Generating return on investment to date • 21 active licensee evaluations post BIO2023 AD-214 Phase II • One party testing AD-214 in own assay
Slide 26: Upcoming milestones and objectives in 2024
Upcoming milestones and objectives in 2024 1. Realise the value of AD-214 v Complete Phase I extension study v Secure AD-214 pathway to Phase II clinical studies ü Full safety and immune response results Q1 2024 ü Out-license or project finance ü Unlock financing for other strategy pillars v GPCR Th
Slide 27: Experienced in-house team
Experienced in-house team Executing from discovery through product development BOARD EXECUTIVE SCIENTIFIC ADVISORY BOARD Paul MacLeman, DVM Angus Tester, PhD Mick Foley, PhD CHAIR SENIOR MANAGER, FOUNDING CHIEF PROJECTS AND PROGRAMS SCIENTIST Tim Oldham, PhD Janette Dixon, DBA Brian Richardson CEO &
Slide 28: AdAlta's foundations in place for growth
AdAlta’s foundations in place for growth Lead asset AD-214 heading to Phase II (US$4.3b IPF market plus others), substantially de-risked with additional Phase I clinical readouts imminent AD-214 partnering window open with multiple options in play: active market with comparator valuations >US$45m up
Slide 29: www.adalta.com.au
A modern targeting system for next generation drugs AdAlta Ltd (ASX:1AD) Investor Presentation October 2023 For more information please contact: Tim Oldham CEO & Managing Director +61 403 446 665 t.oldham@adalta.com.au Investor Relations The Capital Network Julia Maguire +61 2 8999 3699 julia@thecap
Slide 30: i-bodies are a powerful drug discovery tool to engage targets antibodies can't
i-bodies are a powerful drug discovery tool to engage targets that traditional antibodies can’t Small Molecules Antibodies i-bodies™ Flexible, modular formats Current pipeline focus CAR cell therapy ADC/ radiotherapeutic Bi-specific Unique binding Fc-fusion Avoid off-target ~10% the size of capabili
Slide 31: AdAlta's pipeline so far: Five active assets plus growing i-body inventory
AdAlta’s pipeline so far: Five active assets plus growing i-body® inventory Discovery Non-clinical Clinical Target Product Indication Partner Lead Discovery Preclinical IND enabling Phase I Phase II optimisation Lung, kidney IV Available fibrosis SC to license AD-214 Available CXCR4 Eye fibrosis IVT